ConductScience.org, home

Paper41594255

Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response.

Canillas L and 8 others. Diagnostics (Basel), 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response. Papers, record 41594255. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41594255

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Assessment of Liver Fibrosis Stage and Cirrhosis Regression After Long-Term Follow-Up Following Sustained Virological Response.
PubMed
Journal
Diagnostics (Basel)
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-01-31
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Canillas LLidiahttps://orcid.org/0000-0002-7282-8822
2Naranjo DDolores
3Broquetas TTeresahttps://orcid.org/0000-0002-5935-3076
4Sánchez JJuan
5Pocurull AAnna
6Garrido EEsther
7Fernández RRosa
8Forns XXavier
9Carrión JAJosé Ahttps://orcid.org/0000-0001-7191-6081

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
135120736Baveno VII - Renewing consensus in portal hypertension.J Hepatol2022https://conductscience.org/library/papers/35120736PubMed
231493238Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients.J Gastroenterol2020https://conductscience.org/library/papers/31493238PubMed
319243014Liver biopsy.Hepatology2009https://conductscience.org/library/papers/19243014PubMed
438521170Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure.J Hepatol2024https://conductscience.org/library/papers/38521170PubMed
533529675Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside.Gastroenterology2021https://conductscience.org/library/papers/33529675PubMed
638845253EASL position paper on clinical follow-up after HCV cure.J Hepatol2024https://conductscience.org/library/papers/38845253PubMed
730141222Similar recovery of liver function after response to all-oral HCV therapy in patients with cirrhosis with and without HIV coinfection.J Viral Hepat2019https://conductscience.org/library/papers/30141222PubMed
831629779Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.J Hepatol2020https://conductscience.org/library/papers/31629779PubMed
932956768EASL recommendations on treatment of hepatitis C: Final update of the series☆.J Hepatol2020https://conductscience.org/library/papers/32956768PubMed
1029235144Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents.Histopathology2018https://conductscience.org/library/papers/29235144PubMed
1133022803A Model Based on Noninvasive Markers Predicts Very Low Hepatocellular Carcinoma Risk After Viral Response in Hepatitis C Virus-Advanced Fibrosis.Hepatology2020https://conductscience.org/library/papers/33022803PubMed
1221354227Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension.J Hepatol2011https://conductscience.org/library/papers/21354227PubMed
1326918878Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation.Histopathology2016https://conductscience.org/library/papers/26918878PubMed
1434525253Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease.Liver Int2021https://conductscience.org/library/papers/34525253PubMed
1540532848Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals.Clin Res Hepatol Gastroenterol2025https://conductscience.org/library/papers/40532848PubMed
1627910154Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV/HCV patients with advanced liver disease.Aliment Pharmacol Ther2017https://conductscience.org/library/papers/27910154PubMed
1733544313Regression of portal hypertension: underlying mechanisms and therapeutic strategies.Hepatol Int2021https://conductscience.org/library/papers/33544313PubMed
1828734831Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis.Gastroenterology2017https://conductscience.org/library/papers/28734831PubMed
1939817915Long-term outcome and risk stratification in compensated advanced chronic liver disease after HCV-cure.Hepatology2025https://conductscience.org/library/papers/39817915PubMed
2017692984Grading and staging systems for inflammation and fibrosis in chronic liver diseases.J Hepatol2007https://conductscience.org/library/papers/17692984PubMed

See all 35 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41594255

GET https://conductscience.org/api/papers/v1/41594255/references?page=2